Solvonis Therapeutics (LSE:SVNS) has spent 2026 trying to show that a small, London-listed drug developer can keep a late-stage psychiatric programme moving on a modest budget. Its half-year report, published on the last day of September, offers a useful test: did the company narrow its losses while still pushing its lead alcohol use disorder candidate forward, and what does its cash position now look like?

What Solvonis does

Solvonis describes itself as a late clinical-stage biopharmaceutical company focused on central nervous system disorders and addiction. Its shares trade on the Main Market of the London Stock Exchange under the ticker SVNS. The pipeline is built around SVN-001, a ketamine-based treatment for severe alcohol use disorder, alongside SVN-002, an oral thin-film esketamine formulation aimed at moderate-to-severe alcohol use disorder in the United States. Earlier-stage work includes SVN-015, which has been expanded into depression and selected for evaluation in a programme funded by the US National Institute on Drug Abuse, and SVN-114, the lead candidate from its post-traumatic stress disorder discovery programme, which is supported by two granted US composition-of-matter patents.

The interim results

On 30 September 2026, Solvonis published unaudited results for the six months ended 30 June 2026. The company reported a loss before tax of £1.437 million, compared with £1.621 million in the first half of 2025, and a loss per share of 0.021p. R&D spending in the period was £426,000, while net cash outflow from operations was £1.067 million.

The Balance Sheet is thin. Cash and cash equivalents stood at £659,000 at 30 June 2026, down from £1.719 million a year earlier, and net Assets were £4.81 million, most of which reflects intangible assets of £5.667 million. After the period end, on 25 August 2026, the company raised £1.3 million by issuing roughly 1.08 billion new shares at 0.12p each. The directors stated that the group "now has sufficient Working Capital to execute its operations over the next 12 months", and said the interim accounts were prepared on a Going Concern basis.

Fresh data on the lead programme

A day earlier, on 29 September 2026, Solvonis released two further analyses of the Phase 2 KARE trial of SVN-001. The company said patients receiving the treatment had 67% fewer heavy drinking days than placebo at weeks 17 to 20, a result it described as statistically significant. Pooled across weeks 17 to 24, the reduction was 55%, which did not reach conventional significance. A second analysis pointed to reductions in craving and rumination at three months. The company also set out an indirect cross-trial comparison with other treatments; such comparisons are not head-to-head trials and should be read with caution. A UK Phase 3 study, MORE-KARE, co-funded by a UK government health funding body, is recruiting 280 participants.

Risks and what to watch

The main uncertainties are clinical and financial. The Phase 3 outcome for SVN-001 will largely determine the programme's prospects, and positive secondary analyses do not ensure success in a larger trial. Financially, the company remains reliant on capital markets, and the August placing at a fraction of a penny illustrates the dilution existing holders have absorbed. Progress on SVN-002 towards US clinical development, following an FDA pre-IND meeting, is another milestone to monitor. Other markers include the pace of MORE-KARE recruitment and the company's stated plan to expand the programme into Europe on the back of the latest KARE analyses.

Conclusion

The half-year figures show Solvonis trimmed its loss slightly while keeping spending concentrated on its alcohol use disorder candidates. The board's working capital statement suggests the August raise has bought around a year of runway, but the company's value still depends on late-stage trial results and on continued access to funding.